Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional TUSCAN Lymphoma Network)-Authors' reply to Morris and colleagues

Eur J Haematol. 2022 Nov;109(5):595-596. doi: 10.1111/ejh.13831. Epub 2022 Jul 28.

Authors

Emanuele Cencini¹, Alberto Fabbri¹

Affiliation

¹ Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy.

PMID: 35848909
DOI: 10.1111/ejh.13831

No abstract available

Publication types

Letter
Multicenter Study
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Humans
Isoquinolines / therapeutic use
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Non-Hodgkin* / drug therapy
Retrospective Studies
Rituximab / therapeutic use

Substances

Isoquinolines
Rituximab
pixantrone